Geovax presents data on geo-cm04s1, a next generation covid-19 vaccine

Presentation made during the 24th annual world vaccine congress atlanta, ga, april 04, 2024 (globe newswire) -- via newmediawire -- geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its chief scientific officer, mark newman, phd, presented data on geo-cm04s1, the company's next-generation covid-19 vaccine candidate, during the 24th annual world vaccine congress in washington, dc. during his presentation, titled “vaccine induction of broadly-specific antibody and t cell responses to combat sars-cov-2 variation”, dr. newman described geovax's development program for geo-cm04s1.
GOVX Ratings Summary
GOVX Quant Ranking